pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Eli Lilly and Co · news · pharmadog
← back to Eli Lilly and Co
News mentioning Eli Lilly and Co
184
stories
17d
Novo’s race to catch Eli Lilly may already be lost
endpoints
18d
Amgen starts MariTide autoinjector study as pivotal readouts approach
biospace
18d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
18d
Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
biospace
19d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
20d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
23d
After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire
endpoints
24d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
24d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
25d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
25d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
25d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
29d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
Oct 23, 26
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
biospace
Oct 22, 26
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
Oct 22, 26
Roche affirms sales outlook amid doubts about its future
biopharma dive
Oct 22, 26
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
Oct 21, 26
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
biopharma dive
Oct 20, 26
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
Oct 19, 26
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
Oct 19, 26
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3
biospace
Oct 19, 26
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
Oct 16, 26
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
biopharma dive
Oct 14, 26
Verastem cancer drug shows early promise in small study
biopharma dive
Oct 13, 26
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
Oct 12, 26
GSK pledges $800M to add biologics production capabilities in Pennsylvania
biospace
Oct 9, 26
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
Oct 9, 26
TRex Bio prices $117M IPO to support immune drug work
biopharma dive
Oct 9, 26
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
endpoints
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
← prev
page 2 of 7
next →